A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy

Epilepsia

Volumn 56, Issue 3, 2015, Pages 450-459

  Werhahn, Konrad J ^a,i   Trinka, Eugen ^b,c   Dobesberger, Judith ^b,c   Unterberger, Iris ^c   Baum, Petra ^d   Deckert Schmitz, Maria ^e   Kniess, Tobias ^f   Schmitz, Bettina ^g   Bernedo, Viviane ^a   Ruckes, Christian ^a   Ehrlich, Anne ^a   Krämer, Günter ^h,j  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e Harlaching Hospital   (Germany)

^f Clinic for Hand Surgery   (Germany)

^g VIVANTES HOSPITAL   (Germany)

^h SWISS EPILEPSY CENTER   (Switzerland)

ⁱ UCB PHARMA   (Belgium)

^j Neurozentrum Bellevue   (Switzerland)

more..

Author keywords

Antiepileptic drugs; Carbamazepine; Elderly; Levetiracetam; Monotherapy

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; ANTICONVULSIVE AGENT;

ADVERSE OUTCOME; AGED; ARTICLE; AUSTRIA; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CONVULSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOCAL EPILEPSY; GERIATRIC PATIENT; GERMANY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; SEIZURE; SWITZERLAND; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; EPILEPSIES, PARTIAL; EUROPE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STATISTICAL MODEL; TIME;

AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925016319     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12926     Document Type: Article

References (34)

1. Hauser WA, Annegers JF, Kurland LT,. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34: 453-468.
2. Pugh MJ, Knoefel JE, Mortensen EM, et al. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc 2009; 57: 237-242.
3. Olafsson E, Ludvigsson P, Gudmundsson G, et al. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 2005; 4: 627-634.
4. Faught E, Richman J, Martin R, et al. Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries. Neurology 2012; 78: 448-453.
5. Gidal BE, French JA, Grossman P, et al. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009; 72: 419-425.
6. Brodie MJ, Elder AT, Kwan P,. Epilepsy in later life. Lancet Neurol 2009; 8: 1019-1030.
7. Huying F, Klimpe S, Werhahn KJ,. Antiepileptic drug use in nursing home residents: a cross-sectional, regional study. Seizure 2006; 15: 194-197.
8. Johnell K, Fastbom J,. Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden. Drugs Aging 2012; 29: 751-758.
9. Galimberti CA, Magri F, Magnani B, et al. Antiepileptic drug use and epileptic seizures in elderly nursing home residents: a survey in the province of Pavia, Northern Italy. Epilepsy Res 2006; 68: 1-8.
10. Huber DP, Griener R, Trinka E,. Antiepileptic drug use in Austrian nursing home residents. Seizure 2013; 22: 24-27.
11. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug use in nursing home admissions. Ann Neurol 2003; 54: 75-85.
12. Johnell K, Fastbom J,. Antiepileptic drug use in community-dwelling and institutionalized elderly: a nationwide study of over 1,300,000 older people. Eur J Clin Pharmacol 2011; 67: 1069-1075.
13. Pugh MJ, Van Cott AC, Cramer JA, et al. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology 2008; 70: 2171-2178.
14. Brodie MJ, Mintzer S, Pack AM, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 2013; 54: 11-27.
15. Vecht CJ, Wagner GL, Wilms EB,. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2: 404-409.
16. Brodie MJ, Overstall PW, Giorgi L,. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81-87.
17. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64: 1868-1873.
18. Saetre E, Perucca E, Isojarvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48: 1292-1302.
19. Werhahn KJ, Klimpe S, Balkaya S, et al. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure 2011; 20: 305-311.
20. Affairs UN-DoEaS. World Population Ageing 2013 ST/ESA/SER.A/348; 2013.
21. Fisher RS, van Boas Emde W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-472.
22. Fisher RS, Acevedo C, Arzimanoglou A, et al. A practical clinical definition of epilepsy. Epilepsia 2014; 55: 475-482.
23. Alsaadi TM, Koopmans S, Apperson M, et al. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure 2004; 13: 58-60.
24. Cramer JA, Leppik IE, Rue KD, et al. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003; 56: 135-145.
25. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120.
26. SmPC C,. Carbamazepine controlled-release summay of product characteristics.
27. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408.
28. SmPC L,. Lamotrigine summay of product characteristics.
29. SmPC L,. Levetiracetam summay of product characteristics.
30. Ficker DM, Privitera M, Krauss G, et al. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 2005; 65: 593-595.
31. Reunanen M, Dam M, Yuen AW,. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149-155.
32. Bjornsson E,. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008; 118: 281-290.
33. Arif H, Buchsbaum R, Pierro J, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 2010; 67: 408-415.
34. Kim LG, Johnson TL, Marson AG, et al. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006; 5: 317-322.